2011

• Altug, C.et al. 2011. An efficient one-pot multicomponent approach to 5-amino-7-aryl-8-nitrothiazolo[3,2-a]pyridines. Tetrahedron 67(49), pp. 9522-9528. (10.1016/j.tet.2011.10.005)

2010

• Burnett, A. K.et al. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115(5), pp. 948-956. (10.1182/blood-2009-08-236588)
• Burnett, A. K.et al. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115(5), pp. 948-956. (10.1182/blood-2009-08-236588)

2008

• Guy, C.et al. 2008. The impact of MN1 over-expression on the outcome of younger patients with AML treated with intensive chemotherapy with or without ATRA therapy [Abstract]. Blood -New York- 112(11), pp. 1023-1023.

2006

• Wilson, C. H.et al. 2006. Tsc1 Haploinsufficiency without Mammalian Target of Rapamycin Activation Is Sufficient for Renal Cyst Formation in Tsc1+/- Mice. Cancer Research 66(16), pp. 7934-8. (10.1158/0008-5472.CAN-06-1740)

2005

• Wilson, C. H.et al. 2005. Induction of renal tumorigenesis with elevated levels of somatic loss of heterozygosity in Tsc1+/- mice on a Blm-deficient background. Cancer Research 65(22), pp. 10179-10182. (10.1158/0008-5472.CAN-05-2688)
• Buckland, P. R.et al. 2005. Strong bias in the location of functional promoter polymorphisms. Human Mutation 26(3), pp. 214-223. (10.1002/humu.20207)
• Wilson, C. H.et al. 2005. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Human Molecular Genetics 14(13), pp. 1839-1850. (10.1093/hmg/ddi190)
• Buckland, P. R.et al. 2005. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. American Journal of Psychiatry 162(3), pp. 613-615. (10.1176/appi.ajp.162.3.613)

2004

• Hoogendoorn, B.et al. 2004. Functional analysis of polymorphisms in the promoter regions of genes on 22q11. Human Mutation 24(1), pp. 35-42. (10.1002/humu.20061)
• Monslow, J.et al. 2004. Identification and analysis of the promoter region of the human hyaluronan synthase 2 gene. The Journal of Biological Chemistry 279(20), pp. 20576-20581. (10.1074/jbc.M312666200)
• Guy, C.et al. 2004. Promoter polymorphisms in glutathione-S-transferase genes affect transcription. Pharmacogenetics 14(1), pp. 45-51. (10.1097/00008571-200401000-00005)

2003

• Smith, S. K.et al. 2003. Lack of functional promoter polymorphisms in genes involved in glutamate neurotransmission. Psychiatric Genetics 13(4), pp. 193-199. (10.1097/00041444-200312000-00001)
• Hoogendoorn, B.et al. 2003. Functional analysis of human promoter polymorphisms. Human Molecular Genetics 12(18), pp. 2249-2254. (10.1093/hmg/ddg246)
• Monslow, J.et al. 2003. The human hyaluronan synthase genes: genomic structures, proximal promoters and polymorphic microsatellite markers. The International Journal of Biochemistry & Cell Biology 35(8), pp. 1272-1283. (10.1016/S1357-2725(03)00048-7)
• Buckland, P. R.et al. 2003. A high proportion of chromosome 21 promoter polymorphisms influence transcriptional activity. Gene Expression 11(5), pp. 233-239. (10.3727/000000003783992225)

2002

• Coleman, S. L.et al. 2002. Streamlined approach to functional analysis of promoter-region polymorphisms. Biotechniques 33(2), pp. 412-418.
• Anney, R.et al. 2002. Characterisation, mutation detection, and association analysis of alternative promoters and 5' UTRs of the human dopamine D3 receptor gene in schizophrenia. Molecular psychiatry 7(5), pp. 493-502. (10.1038/sj.mp.4001003)
• Coleman, S. L.et al. 2002. Experimental analysis of the annotation of promoters in the public database. Human Molecular Genetics 11(16), pp. 1817-1821. (10.1093/hmg/11.16.1817)

2000

• Vincent, J. B.et al. 2000. Long repeat tracts at SCA8 in major psychosis. American Journal of Medical Genetics 96(6), pp. 873-876. (10.1002/1096-8628(20001204)96:6<873::AID-AJMG37>3.0.CO;2-9)
• Bowen, T.et al. 2000. No evidence of association from transmission disequilibrium analysis of the hKCa3 gene in bipolar disorder. Bipolar Disorders 2(4), pp. 328-331. (10.1034/j.1399-5618.2000.020406.x)
• Bowen, T.et al. 2000. Repeat sizes at CAG/CTG loci CTG18.1, ERDA1 and TGC13-7a in schizophrenia. Psychiatric Genetics 10(1), pp. 33-37. (10.1097/00041444-200010010-00006)

1999

• Guy, C.et al. 1999. CTG18.1 and ERDA-1 CAG/CTG repeat size in bipolar disorder. Neurobiology of Disease 6(4), pp. 302-307. (10.1006/nbdi.1999.0249)
• Cardno, A. G.et al. 1999. CAG repeat length in the hKCa3 gene and symptom dimensions in schizophrenia. Biological Psychiatry 45(12), pp. 1592-1596. (10.1016/s0006-3223(99)00033-5)
• Franks, E.et al. 1999. Eleven trinucleotide repeat loci that map to chromosome 12 excluded from involvement in the pathogenesis of bipolar disorder. American Journal of Medical Genetics 88(1), pp. 67-70. (10.1002/(SICI)1096-8628(19990205)88:1<67::AID-AJMG12>3.0.CO;2-#)
• Guy, C.et al. 1999. No association between a polymorphic CAG repeat in the human potassium channel gene hKCa3 and bipolar disorder. American Journal of Medical Genetics 88(1), pp. 57-60. (10.1002/(sici)1096-8628(19990205)88:1%3C57::aid-ajmg10%3E3.0.co;2-6)

1998

• Bowen, T.et al. 1998. Further support for an association between a polymorphic CAG repeat in the hKCa3 gene and schizophrenia. Molecular Psychiatry 3(3), pp. 266-269. (10.1038/sj.mp.4000400)
• Bowen, T.et al. 1998. Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder. Molecular Psychiatry 3(1), pp. 67-71. (10.1038/sj.mp.4000293)
• Cardno, A. G.et al. 1998. Association between functional psychosis and expanded CAG/CTG repeats is not explained by health stratification [comparative study]. Psychiatric Genetics 8(1), pp. 29-32. (10.1097/00041444-199800810-00005)

1997

• Jones, L.et al. 1997. No evidence for expanded polyglutamine sequences in bipolar disorder and schizophrenia. Molecular Psychiatry 2(6), pp. 478-482. (10.1038/sj.mp.4000297)
• Craddock, N. J.et al. 1997. Expanded CAG/CTG repeats in bipolar disorder: no correlation with phenotypic measures of illness severity. Biological psychiatry 42(10), pp. 876-881. (10.1016/s0006-3223(96)00516-1)
• Guy, C.et al. 1997. Exclusion of expansion of 50 CAG/CTG trinucleotide repeats in bipolar disorder. American Journal of Psychiatry 154(8), pp. 1146-1147.
• Speight, G.et al. 1997. Exclusion of CAG/CTG trinucleotide repeat loci which map to chromosome 4 in bipolar disorder and schizophrenia. American Journal of Medical Genetics 74(2), pp. 204-206. (10.1002/(SICI)1096-8628(19970418)74:2<204::AID-AJMG19>3.0.CO;2-M)

1996

• O'Donovan, M. C.et al. 1996. Involvement of expanded trinucleotide repeats in common diseases. The Lancet 348(9043), pp. 1739-1740. (10.1016/s0140-6736(05)65870-9)
• O'Donovan, M. C.et al. 1996. Confirmation of association between expanded CAG/CTG repeats and both schizophrenia and bipolar disorder. Psychological Medicine -London- 26(6), pp. 1145-1153. (10.1017/s0033291700035868)
• Bowen, T.et al. 1996. Expansion of 50 CAG/CTG repeats excluded in schizophrenia by application of a highly efficient approach using repeat expansion detection and a PCR screening set. American Journal of Human Genetics 59(4), pp. 912-917.

1995

• O'Donovan, M. C.et al. 1995. Expanded CAG repeats in schizophrenia and bipolar disorder [letter]. Nature Genetics 10(4), pp. 380-381. (10.1038/ng0895-380)